SVRA: Savara Corp Price to Sales
Savara Inc. aims for dominance in the therapy of rare pulmonary proteinosis by implementing targeted delivery of biologics to inflammation sites. The GURU.Markets portal displays this P/S time series, where the metric value of captures the current revenue valuation. Since the company is in the pre-commercial stage, future price momentum depends directly on final regulatory decisions.
Analytical breakdowns for Savara Corp (SVRA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- net income and valuation ratios data:
SVRA - Net Profit|Company Profit Forecast Savara Inc.|SVRA - Price to Earnings Ratio|Price to Future Earnings Ratio Savara Inc|SVRA - PEG Multiple|Enterprise Value to EBITDA Ratio Savara Corp|SVRA - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Savara|SVRA - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months savarapharma.com|SVRA - Net earnings per share growth this year|Net earnings per share growth forecast for next year Savara Inc.
- issuer revenue and sales details:
Fundamental company analysis:savarapharma.com, SVRA
The P/S ratio is calculated as the ratio of Savara Inc. (SVRA) market capitalization to its annual revenue, determining the value of one dollar of sales in the eyes of investors. Analyzing the price-to-sales ratio allows for an assessment of the efficiency of biopharmaceutical logistics costs, where the stability of clinic supplies directly impacts the asset's fundamental resilience and the justification of current market valuations.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|kiniksa.com (KNSA) - P/S Multiple|Market Cap to Revenue GRFS|Price-to-Revenue Ratio ADPT|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|IMNM - Market Cap to Revenue|GOSS: Market Cap to Revenue|Price-to-Revenue Coefficient kalvista.com KALV|Septerna (SEPN) - Price-to-Revenue Ratio|PVLA - Price-to-Revenue Coefficient|Market Cap to Revenue RIGL|Price-to-Revenue Ratio ANAB|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN (engene.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RAPT (RAPT Therapeutics)|P/S Multiple Aerovate Therapeutics, Inc. JBIO|ACRS - Price-to-Revenue Ratio|Price-to-Sales Ratio KYTX|TLSA: P/S Multiple|cabalettabio.com - Market Capitalization-to-Revenue Ratio|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|P/S Multiple Theratechnologies, Inc.|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Agenus AGEN|CLYM - Market Cap to Revenue|Zura Bio - P/S Multiple|ATYR - P/S Multiple|ADAG (adagene.com) - Market Cap to Revenue|Ikena Oncology - Market Capitalization-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|Equillium Bio (EQ) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Market Cap to Revenue immunic-therapeutics.com IMUX|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|XFOR: Market Cap to Revenue|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio INMB|BRNS (Barinthus Bio) - P/S Multiple|Price to Sales Kezar Life Sciences Inc KZR|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Price-to-Revenue Coefficient akaritx.com|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|P/S Multiple Q32 Bio Inc QTTB|GOVX: Market Cap to Revenue|EDSA: Price-to-Revenue Ratio|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Coefficient affimed.com|Price-to-Revenue Ratio Allakos ALLK|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS: Market Cap to Revenue|ITOS: Price-to-Revenue Ratio|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
